Barré Tangui, Bourlière Marc, Ramier Clémence, Carrat Fabrice, Di Beo Vincent, Protopopescu Camelia, Marcellin Fabienne, Bureau Morgane, Cagnot Carole, Dorival Céline, Zoulim Fabien, Zucman-Rossi Jessica, Duclos-Vallée Jean-Charles, Fontaine Hélène, Carrieri Patrizia
Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l'Information Médicale, ISSPAM, 13005 Marseille, France.
Hôpital St. Joseph, Service d'Hépato-Gastroentérologie, 13008 Marseille, France.
J Clin Med. 2022 Oct 18;11(20):6135. doi: 10.3390/jcm11206135.
Hepatitis C virus (HCV) infection is associated with the onset of metabolic disorders which constitute risk factors for liver disease progression. Their impact may persist after the HCV infection has been cured. Cannabis use is associated with a lower risk of obesity and diabetes in both general and HCV populations. The associations between cannabis use and both dyslipidemia and hypertension have not yet been studied in persons with chronic HCV infection.
Using cross-sectional data from the French ANRS CO22 Hepather cohort, we used regression models to test for an inverse relationship between cannabis use and (i) dyslipidemia, (ii) hypertension, and (iii) the total number of metabolic disorders.
Among the 6364 participants in the study population, both former and current cannabis use were associated with a lower risk of hypertension and fewer metabolic disorders. These results were independent of central obesity. Cannabis use was not associated with dyslipidemia.
In people chronically infected with HCV, cannabis use was associated with a lower risk of hypertension and a lower number of metabolic disorders. Post-HCV cure studies are needed to confirm these findings using longitudinal data and to test whether they translate into reduced mortality in this population.
丙型肝炎病毒（HCV）感染与代谢紊乱的发生有关，而代谢紊乱是肝病进展的危险因素。即使HCV感染已治愈，其影响仍可能持续存在。在普通人群和HCV感染人群中，使用大麻都与肥胖和糖尿病风险降低有关。慢性HCV感染者中，大麻使用与血脂异常和高血压之间的关联尚未得到研究。
利用法国国家艾滋病和肝炎研究机构（ANRS）CO22 Hepather队列的横断面数据，我们使用回归模型来检验大麻使用与（i）血脂异常、（ii）高血压以及（iii）代谢紊乱总数之间的负相关关系。
在研究人群的6364名参与者中，既往和当前使用大麻均与高血压风险降低和代谢紊乱较少有关。这些结果与中心性肥胖无关。大麻使用与血脂异常无关。
在慢性HCV感染者中，使用大麻与高血压风险降低和代谢紊乱数量减少有关。需要进行HCV治愈后的研究，以利用纵向数据证实这些发现，并测试它们是否能转化为该人群死亡率的降低。
